{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:30:25Z","timestamp":1790191825012,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research","award":["20K07594"],"award-info":[{"award-number":["20K07594"]}]},{"name":"JST SPRING","award":["JPMJSP2127 (to XY.W.)"],"award-info":[{"award-number":["JPMJSP2127 (to XY.W.)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1245\/s10434-025-17247-3","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T15:45:31Z","timestamp":1743349531000},"page":"5991-6004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["AT101 Suppresses Gastrointestinal Stromal Tumor Growth and Promotes Apoptosis via YAP\/TAZ\u2013CCND1 and FBXW7\u2013MCL1 Axes"],"prefix":"10.1245","volume":"32","author":[{"given":"Xiyu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyue","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-4618","authenticated-orcid":false,"given":"Masaaki","family":"Iwatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"17247_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","volume":"40","author":"K Soreide","year":"2016","unstructured":"Soreide K, Sandvik OM, Soreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39\u201346.","journal-title":"Cancer Epidemiol."},{"issue":"19","key":"17247_CR2","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1158\/1078-0432.CCR-20-1706","volume":"26","author":"C Serrano","year":"2020","unstructured":"Serrano C, George S. Gastrointestinal stromal tumor: challenges and opportunities for a new decade. Clin Cancer Res. 2020;26(19):5078\u201385.","journal-title":"Clin Cancer Res."},{"issue":"12","key":"17247_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.2012.347","volume":"307","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265\u201372.","journal-title":"JAMA."},{"issue":"4","key":"17247_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(05)70097-8","volume":"6","author":"E Wardelmann","year":"2005","unstructured":"Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005;6(4):249\u201351.","journal-title":"Lancet Oncol."},{"issue":"5","key":"17247_CR5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.6004\/jnccn.2017.0057","volume":"15","author":"M Alkhuziem","year":"2017","unstructured":"Alkhuziem M, Burgoyne AM, Fanta PT, Tang CM, Sicklick JK. The call of \u201cthe wild\u201d-type GIST: it\u2019s time for domestication. J Natl Compr Canc Netw. 2017;15(5):551\u20134.","journal-title":"J Natl Compr Canc Netw."},{"issue":"12","key":"17247_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"CL Corless","year":"2011","unstructured":"Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11(12):865\u201378.","journal-title":"Nat Rev Cancer."},{"issue":"39","key":"17247_CR7","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.1038\/s41388-019-0894-3","volume":"38","author":"WB Ou","year":"2019","unstructured":"Ou WB, Ni N, Zuo R, et al. Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene. 2019;38(39):6615\u201329.","journal-title":"Oncogene."},{"issue":"2","key":"17247_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrc.2015.17","volume":"16","author":"AR Delbridge","year":"2016","unstructured":"Delbridge AR, Grabow S, Strasser A, Vaux DL. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16(2):99\u2013109.","journal-title":"Nat Rev Cancer."},{"issue":"8","key":"17247_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrc.2016.58","volume":"16","author":"G Ichim","year":"2016","unstructured":"Ichim G, Tait SW. A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer. 2016;16(8):539\u201348.","journal-title":"Nat Rev Cancer."},{"key":"17247_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.pharmthera.2014.08.003","volume":"145","author":"J Belmar","year":"2015","unstructured":"Belmar J, Fesik SW. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther. 2015;145:76\u201384.","journal-title":"Pharmacol Ther."},{"issue":"1","key":"17247_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2005.09.010","volume":"44","author":"W Sieghart","year":"2006","unstructured":"Sieghart W, Losert D, Strommer S, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol. 2006;44(1):151\u20137.","journal-title":"J Hepatol."},{"issue":"10","key":"17247_CR12","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41416-020-0795-9","volume":"122","author":"A Bierbrauer","year":"2020","unstructured":"Bierbrauer A, Jacob M, Vogler M, Fulda S. A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. Br J Cancer. 2020;122(10):1544\u201351.","journal-title":"Br J Cancer."},{"issue":"2","key":"17247_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10120-023-01454-6","volume":"27","author":"X Wu","year":"2024","unstructured":"Wu X, Iwatsuki M, Takaki M, et al. FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1. Gastric Cancer. 2024;27(2):235\u201347.","journal-title":"Gastric Cancer."},{"issue":"5540","key":"17247_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1126\/science.1065203","volume":"294","author":"DM Koepp","year":"2001","unstructured":"Koepp DM, Schaefer LK, Ye X, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001;294(5540):173\u20137.","journal-title":"Science."},{"issue":"5","key":"17247_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrc1881","volume":"6","author":"KI Nakayama","year":"2006","unstructured":"Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6(5):369\u201381.","journal-title":"Nat Rev Cancer."},{"issue":"6","key":"17247_CR16","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10120-019-00950-y","volume":"22","author":"Y Koga","year":"2019","unstructured":"Koga Y, Iwatsuki M, Yamashita K, et al. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer. 2019;22(6):1100\u20138.","journal-title":"Gastric Cancer."},{"issue":"5895","key":"17247_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1126\/science.1162981","volume":"321","author":"JH Mao","year":"2008","unstructured":"Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499\u2013502.","journal-title":"Science."},{"issue":"9","key":"17247_CR18","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/0008-5472.CAN-16-3242","volume":"77","author":"J Tong","year":"2017","unstructured":"Tong J, Wang P, Tan S, et al. Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer Res. 2017;77(9):2512\u201321.","journal-title":"Cancer Res."},{"issue":"7336","key":"17247_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature09732","volume":"471","author":"H Inuzuka","year":"2011","unstructured":"Inuzuka H, Shaik S, Onoyama I, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471(7336):104\u20139.","journal-title":"Nature."},{"issue":"11","key":"17247_CR20","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-14-2191","volume":"21","author":"S Song","year":"2015","unstructured":"Song S, Honjo S, Jin J, et al. The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin Cancer Res. 2015;21(11):2580\u201390.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"17247_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","volume":"15","author":"T Moroishi","year":"2015","unstructured":"Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15(2):73\u20139.","journal-title":"Nat Rev Cancer."},{"issue":"3","key":"17247_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","volume":"47","author":"L Lin","year":"2015","unstructured":"Lin L, Sabnis AJ, Chan E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015;47(3):250\u20136.","journal-title":"Nat Genet."},{"issue":"3","key":"17247_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/ng.3228","volume":"47","author":"A Keren-Paz","year":"2015","unstructured":"Keren-Paz A, Emmanuel R, Samuels Y. YAP and the drug resistance highway. Nat Genet. 2015;47(3):193\u20134.","journal-title":"Nat Genet."},{"issue":"11","key":"17247_CR24","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.neo.2016.08.009","volume":"18","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Zhang Y, Parsels JD, et al. Fbxw7 deletion accelerates Kras(G12D)-driven pancreatic tumorigenesis via Yap accumulation. Neoplasia. 2016;18(11):666\u201373.","journal-title":"Neoplasia."},{"issue":"10","key":"17247_CR25","doi-asserted-by":"publisher","first-page":"6980","DOI":"10.1074\/jbc.M112.414177","volume":"288","author":"M Boiani","year":"2013","unstructured":"Boiani M, Daniel C, Liu X, Hogarty MD, Marnett LJ. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. J Biol Chem. 2013;288(10):6980\u201390.","journal-title":"J Biol Chem."},{"issue":"3","key":"17247_CR26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/0008-5472.CAN-10-2873","volume":"72","author":"A Imai","year":"2012","unstructured":"Imai A, Zeitlin BD, Visioli F, et al. Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. Cancer Res. 2012;72(3):716\u201325.","journal-title":"Cancer Res."},{"issue":"12","key":"17247_CR27","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1136\/gutjnl-2020-321175","volume":"70","author":"S Song","year":"2021","unstructured":"Song S, Chen Q, Li Y, et al. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut. 2021;70(12):2238\u201348.","journal-title":"Gut."},{"issue":"11","key":"17247_CR28","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1182\/blood-2007-12-129833","volume":"111","author":"L Paoluzzi","year":"2008","unstructured":"Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood. 2008;111(11):5350\u20138.","journal-title":"Blood."},{"issue":"1","key":"17247_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1182\/blood-2008-02-138560","volume":"113","author":"K Balakrishnan","year":"2009","unstructured":"Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood. 2009;113(1):149\u201353.","journal-title":"Blood."},{"issue":"4","key":"17247_CR30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/JTO.0b013e31820a0ea6","volume":"6","author":"N Ready","year":"2011","unstructured":"Ready N, Karaseva NA, Orlov SV, et al. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol. 2011;6(4):781\u20135.","journal-title":"J Thorac Oncol."},{"issue":"12","key":"17247_CR31","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/ijc.34461","volume":"152","author":"R Teranishi","year":"2023","unstructured":"Teranishi R, Takahashi T, Obata Y, et al. Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. Int J Cancer. 2023;152(12):2580\u201393.","journal-title":"Int J Cancer."},{"issue":"7","key":"17247_CR32","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1093\/annonc\/mdr622","volume":"23","author":"JY Blay","year":"2012","unstructured":"Blay JY, Perol D, Le Cesne A. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. Ann Oncol. 2012;23(7):1659\u201365.","journal-title":"Ann Oncol."},{"issue":"10","key":"17247_CR33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S1470-2045(10)70222-9","volume":"11","author":"A Le Cesne","year":"2010","unstructured":"Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11(10):942\u20139.","journal-title":"Lancet Oncol."},{"issue":"4","key":"17247_CR34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626\u201332.","journal-title":"J Clin Oncol."},{"issue":"11","key":"17247_CR35","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","volume":"11","author":"CR Antonescu","year":"2005","unstructured":"Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11(11):4182\u201390.","journal-title":"Clin Cancer Res."},{"issue":"7","key":"17247_CR36","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"JY Blay","year":"2020","unstructured":"Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923\u201334.","journal-title":"Lancet Oncol."},{"issue":"7","key":"17247_CR37","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","volume":"21","author":"MC Heinrich","year":"2020","unstructured":"Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21(7):935\u201346.","journal-title":"Lancet Oncol."},{"issue":"5","key":"17247_CR38","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","volume":"35","author":"BD Smith","year":"2019","unstructured":"Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) Is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell. 2019;35(5):738\u201351.","journal-title":"Cancer Cell."},{"issue":"24","key":"17247_CR39","doi-asserted-by":"publisher","first-page":"7287","DOI":"10.1158\/1078-0432.CCR-19-2150","volume":"25","author":"C Serrano","year":"2019","unstructured":"Serrano C, Leal A, Kuang Y, et al. Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine kinase inhibitor refractory gastrointestinal stromal tumors. Clin Cancer Res. 2019;25(24):7287\u201393.","journal-title":"Clin Cancer Res."},{"issue":"33","key":"17247_CR40","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352\u20139.","journal-title":"J Clin Oncol."},{"issue":"2","key":"17247_CR41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1053\/j.gastro.2004.11.020","volume":"128","author":"M Debiec-Rychter","year":"2005","unstructured":"Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128(2):270\u20139.","journal-title":"Gastroenterology."},{"issue":"23","key":"17247_CR42","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1080\/15384101.2018.1553335","volume":"17","author":"Y Tu","year":"2018","unstructured":"Tu Y, Zuo R, Ni N, et al. Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression. Cell Cycle. 2018;17(23):2577\u201392.","journal-title":"Cell Cycle."},{"issue":"10","key":"17247_CR43","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.5858\/2006-130-1466-GSTROM","volume":"130","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466\u201378.","journal-title":"Arch Pathol Lab Med."},{"issue":"48","key":"17247_CR44","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1038\/s41388-021-02049-0","volume":"40","author":"A Garcia-Valverde","year":"2021","unstructured":"Garcia-Valverde A, Rosell J, Sayols S, et al. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. Oncogene. 2021;40(48):6614\u201326.","journal-title":"Oncogene."},{"key":"17247_CR45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-pathol-042220-021510","volume":"17","author":"JK Dermawan","year":"2022","unstructured":"Dermawan JK, Rubin BP. Molecular pathogenesis of gastrointestinal stromal tumor: a paradigm for personalized medicine. Annu Rev Pathol. 2022;17:323\u201344.","journal-title":"Annu Rev Pathol."},{"issue":"13","key":"17247_CR46","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.3390\/cancers15133468","volume":"15","author":"RB Mokhtari","year":"2023","unstructured":"Mokhtari RB, Ashayeri N, Baghaie L, et al. The Hippo pathway effectors YAP\/TAZ-TEAD oncoproteins as emerging therapeutic targets in the tumor microenvironment. Cancers. 2023;15(13):3468.","journal-title":"Cancers."},{"issue":"8","key":"17247_CR47","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrc3090","volume":"11","author":"EA Musgrove","year":"2011","unstructured":"Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11(8):558\u201372.","journal-title":"Nat Rev Cancer."},{"issue":"24","key":"17247_CR48","doi-asserted-by":"publisher","first-page":"11513","DOI":"10.1073\/pnas.90.24.11513","volume":"90","author":"JY Kato","year":"1993","unstructured":"Kato JY, Sherr CJ. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc Natl Acad Sci U S A. 1993;90(24):11513\u20137.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"20","key":"17247_CR49","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.4161\/15384101.2014.950126","volume":"13","author":"E Tarasewicz","year":"2014","unstructured":"Tarasewicz E, Rivas L, Hamdan R, et al. Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells. Cell Cycle. 2014;13(20):3191\u2013201.","journal-title":"Cell Cycle."},{"issue":"5","key":"17247_CR50","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ccr.2011.10.001","volume":"20","author":"L Anders","year":"2011","unstructured":"Anders L, Ke N, Hydbring P, et al. A systematic screen for CDK4\/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011;20(5):620\u201334.","journal-title":"Cancer Cell."},{"issue":"11","key":"17247_CR51","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1128\/MCB.02124-05","volume":"26","author":"Z Li","year":"2006","unstructured":"Li Z, Wang C, Jiao X, et al. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol. 2006;26(11):4240\u201356.","journal-title":"Mol Cell Biol."},{"key":"17247_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.686874","volume":"12","author":"T Chen","year":"2021","unstructured":"Chen T, Ni N, Yuan L, et al. Proteasome inhibition suppresses KIT-independent gastrointestinal stromal tumors via targeting Hippo\/YAP\/Cyclin D1 signaling. Front Pharmacol. 2021;12:686874.","journal-title":"Front Pharmacol."},{"issue":"8","key":"17247_CR53","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3390\/cancers12082298","volume":"12","author":"DJ Mallick","year":"2020","unstructured":"Mallick DJ, Eastman A. AT101 [(-)-Gossypol] selectively inhibits mcl1 and sensitizes carcinoma to BH3 mimetics by inducing and stabilizing NOXA. Cancers. 2020;12(8):2298.","journal-title":"Cancers."},{"issue":"23","key":"17247_CR54","doi-asserted-by":"publisher","first-page":"34430","DOI":"10.18632\/oncotarget.9119","volume":"7","author":"X Wei","year":"2016","unstructured":"Wei X, Duan W, Li Y, et al. AT101 exerts a synergetic efficacy in gastric cancer patients with 5-FU based treatment through promoting apoptosis and autophagy. Oncotarget. 2016;7(23):34430\u201341.","journal-title":"Oncotarget."},{"issue":"3","key":"17247_CR55","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.CD-14-0625","volume":"5","author":"Y Li","year":"2015","unstructured":"Li Y, Chitnis N, Nakagawa H, et al. PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers. Cancer Discov. 2015;5(3):288\u2013303.","journal-title":"Cancer Discov."},{"issue":"5","key":"17247_CR56","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3390\/ijms18050961","volume":"18","author":"M Ferraiuolo","year":"2017","unstructured":"Ferraiuolo M, Verduci L, Blandino G, Mutant S. Mutant p53 protein and the Hippo transducers YAP and TAZ: a critical oncogenic node in human cancers. Int J Mol Sci. 2017;18(5):961.","journal-title":"Int J Mol Sci."},{"issue":"2","key":"17247_CR57","first-page":"1415","volume":"41","author":"F Que","year":"2019","unstructured":"Que F, Dai L, Zhou D, et al. AT-101 induces G1\/G0 phase arrest via the beta-catenin\/cyclin D1 signaling pathway in human esophageal cancer cells. Oncol Rep. 2019;41(2):1415\u201323.","journal-title":"Oncol Rep."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17247-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17247-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17247-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T13:59:33Z","timestamp":1751464773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17247-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["17247"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17247-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"29 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Ethics approval of this study was granted by the ethics committee at Kumamoto University Hospital (approval numbers: 2143). The study was conducted in accordance with the Declaration of Helsinki principles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}